

COMPARE-1 CLINICAL TRIAL


TWO YEAR RESULTS FROM PILOT PHASE PRESENTED AT LINC 2019¹

TRIAL DESIGN:

WORLD'S FIRST Head-to-Head Prospective, **RANDOMIZED (1:1) CONTROLLED** Trial comparing the lower dose Paclitaxel RANGER DCB (2 µg/mm²) to the higher dose Paclitaxel IN.PACT DCB (3.5 µg/mm²)

TWO YEAR RESULTS:

**Similar Patency ($p=0.57^*$),
with significantly less drug**



The new generation, lower dose, Ranger DCB demonstrated similar Patency with significantly less drug compared to the higher dose IN.PACT DCB.

¹Results from the 150 patient pilot phase. Overall trial will enroll up to 414 patients.
*p-value based on log-rank test

COMPARE-1 CLINICAL TRIAL

TRIAL DETAILS

OBJECTIVE:

To compare two different Paclitaxel coated balloons (with different coatings and different Paclitaxel dose density) in the treatment of high grade stenotic or occluded lesions in SFA and/or PPA in PAD patients with Rutherford class 2-4.

TRIAL DESIGN:

- Prospective, multicenter, randomized trial
- Randomization 1:1
- Phase 1: Pilot Study (150 patients)
- Phase 2: Extension (up to 414 patients) for testing of a formal non-inferiority hypothesis
- Stratification according to lesion length
- Follow-up clinical visits at 6, 12, 24 months

	Ranger™	IN.PACT™
Drug Dose	2.0 µg/mm ²	3.5 µg/mm ²
Longest Length Available	200 mm	150 mm
Platform	Sterling™	Admiral™ or Pacific™
Excipient	TransPax™	Urea

BASELINE CHARACTERISTICS	Ranger™ (n=74)	IN.PACT™ (n=76)	p-value
Total Occlusions	39%	45%	0.5
Total Occlusion Length	111 mm	95 mm	0.5
Target Lesion Length	117 mm	122 mm	0.8
Moderate to Severe Calcification	58%	61%	0.7*
Diabetics	34%	37%	0.7

* p-value includes all categories of calcification

KEY ENROLLMENT CRITERIA:

- Rutherford 2, 3 or 4
- Stenotic, restenotic or occlusive lesions ($\geq 70\%$ stenosis) in the native non-stented SFA/PPA
- No prior treatment with drug coated balloons or drug-eluting stents in the treated limb
- Lesion ≤ 300 mm, RVD ≥ 4 mm and ≤ 6.5 mm

DEFINITIONS:

Patency — Core lab adjudicated (12 months):

Efficacy: patency rate after one year defined as absence of clinically driven Target Lesion Revascularization (due to symptoms and drop of ABL of $\geq 20\%$ or > 0.15 when compared to post-procedure) or restenosis with Peak Velocity Ratio > 2.4 evaluated by Duplex Ultrasound

Ranger™ Paclitaxel Coated PTA Balloon Catheter is manufactured by Hemotek AG and distributed by Boston Scientific Corporation. All cited trademarks are the property of their respective owners.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not for use or distribution in France.

**Boston
Scientific**
Advancing science for life™

www.bostonscientific.eu

© 2019 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI-601911-AA JAN2019